A prospective study on patterns of topical steroids self-use in dermatophytoses and determinants predictive of cutaneous side effects.
India
abuse
cutaneous side effects
dermatophytoses
discontinuous
intermittent
misuse
potent steroid
recalcitrant
tinea
topical steroid
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
09
04
2020
revised:
11
05
2020
accepted:
15
05
2020
pubmed:
26
5
2020
medline:
15
5
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Nonprescription use of topical corticosteroids (TCS) is a significant concern. This can lead to cutaneous adverse effects, altered morphology of skin disorders and chronicity of cutaneous infections. To record and analyze the patterns of TCS use in patients with tinea corporis/cruris and analyze factors determining the development of cutaneous side effects. Hundred patients with a clinical diagnosis of tinea corporis/cruris who could recall the TCS preparation/s used were included. The TCS usage patterns were recorded and analyzed. Most patients had used very potent TCS (n = 66). Most reported using TCS intermittently for duration ranging from 1 to 4 weeks (n = 78). Relapse of symptoms occurred within 1 to 2 weeks of stopping TCS, triggering reuse. Cutaneous adverse effects were present in 44 patients (striae [n = 29], hypo/depigmentation [n = 11], skin thinning [n = 8], hypertrichosis [n = 1], tinea pseudoimbricata [n = 1]). There was a significant correlation between presence of cutaneous adverse effects and the total duration of TCS use (P = .0016), duration of disease (P = .016), and total amount of TCS used (P = .012). Use for >60 days and of >32 g were associated with 89% and 96.3% (respectively) probability of developing cutaneous adverse effects. Self-use of TCS is a worrisome trend. Intermittent use is a plausible reason for development of cutaneous side effects in only 44% patients.
Substances chimiques
Antifungal Agents
0
Steroids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13633Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Meena S, Gupta LK, Khare AK, et al. Topical corticosteroids abuse: a clinical study of cutaneous adverse effects. Indian J Dermatol. 2017;62:675.
Mahar S, Mahajan K, Agarwal S, Kar HK, Bhattacharya SK. Topical corticosteroid misuse: the scenario in patients attending a tertiary care hospital in New Delhi. J Clin Diagn Res. 2016;10:FC16-FC20.
Singh A, Masih A, Monroy-Nieto J, et al. A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: genomic insights and resistance profile. Fungal Genet Biol. 2019;133:103266.
Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: Recent trends and therapeutic implications. Fungal Genet Biol. 2019;132:103255.
Singh A, Masih A, Khurana A, et al. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61:477-484.
Khurana A, Masih A, Chowdhary A, et al. Correlation of in vitro susceptibility based on MICs and squalene epoxidase mutations with clinical response to terbinafine in patients with tinea corporis/cruris. Antimicrob Agents Chemother. 2018;62:e01038-e01018.
Rathi S. Abuse of topical steroid as cosmetic cream: a social background of steroid dermatitis. Ind J Dermatol. 2006;51:154-155.
Saraswat A, Lahiri K, Chatterjee M, et al. Topical corticosteroid abuse on the face: a prospective, multicenter study of dermatology outpatients. Indian J Dermatol Venereol Leprol. 2011;77:160-166.
Smith ES, Fleischer AB Jr, Feldman SR. Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994. J Am Acad Dermatol. 1998;39:43-47.
https://youtu.be/sGHvmhmYaac. Accessed March 19, 2020.
Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents. Pediatrics. 2003;111:201-203.
Lubach D, Bensmann A, Bornemann U. Steroid-induced dermal atrophy. Dermatologica. 1989;179:67-72.
Lubach D, Rath J, Kietzmann M. Steroid-induced dermal thinning: discontinuous application of clobetasol-17-propionate ointment. Dermatologica. 1992;185:44-48.
Jones W. Steroid atrophy-a histological appraisal. Dermatologica. 1976;152:107-115.
Katz HI, Prawer SE, Mooney JJ, Samson CR. Preatrophy: covert sign of thinned skin. J Am Acad Dermatol. 1989;20:731-735.
Gibson JR, Kirsch JM, Darley CR, et al. An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations. Br J Dermatol. 1984;III:204-212.
Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30:729-747.
Veien NK, Olholm Larsen P, Thestrup-Pedersen K, et al. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol. 1999;140:882-886.
Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol. 1984;120:631-635.
Vickers CF. Existence of reservoir in the stratum corneum: experimental proof. Arch Dermatol. 1963;88:20-23.
Singh SK, Nasir F. The reservoir effect of topical steroids in vitiliginous skin: a cross-sectional study. Indian J Dermatol Venereol Leprol. 2015;81:370-375.
Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea curis, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol. 1996;34:282-286.
Erbagci Z. Topical therapy for dermatophytoses: should corticosteroids be included? Am J Clin Dermatol. 2004;5:375-384.
Smith EB, Breneman DI, Griffith RF, et al. Double-blind comparison of naftifine cream and clotrimazole/betamethasone diproprionate cream in the treatment of tinea pedis. J Am Acad Dermatol. 1992;26:125-127.
Nada M, Hanafi S, Al-Omari H, et al. Naftifine versus miconazole/hydrocortisone in inflammatory dermatophyte infections. Int J Dermatol. 1994;33:570-572.